Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence.

ABSTRACT: Depression is characterized by continuous low mood and loss of interest or pleasure in enjoyable activities. First-line medications for mood disorders mostly target the monoaminergic system; however, many patients do not find relief with these medications, and those who do suffer from negative side effects and a discouragingly low rate of remission. Studies suggest that the endocannabinoid system (ECS) may be involved in the etiology of depression and that targeting the ECS has the potential to alleviate depression. ECS components (such as receptors, endocannabinoid ligands, and degrading enzymes) are key neuromodulators in motivation and cognition as well as in the regulation of stress and emotions. Studies in depressed patients and in animal models for depression have reported deficits i

SUBMITTER: Bright U 

PROVIDER: S-EPMC9146799 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature